September 05, 2017
Genomics company Illumina Inc. accused rival Ariosa Diagnostics Inc. on Friday of violating California's anti-SLAPP law by bringing $100 million in counterclaims in Illumina's patent infringement suit, while Ariosa argued for its part Friday that its prenatal testing services plainly did not infringe.
January 27, 2017
Illumina Inc. asked the Federal Circuit Friday to clarify which invalidity arguments the inter partes review estoppel provision bars petitioners from raising in litigation after a patent is reviewed, saying district judges have made "clear and indisputable" errors in allowing too many arguments.
January 23, 2017
A California federal judge has allowed Ariosa Diagnostics Inc. to argue that Illumina Inc. prenatal test patents are invalid on grounds Ariosa included in an inter partes review petition but on which review was not instituted, taking a narrow reading of the America Invents Act's estoppel provision.
November 19, 2014
The Patent Trial and Appeal Board on Wednesday invalidated a prenatal DNA test patent owned by Stanford University in a victory for accused infringer Ariosa Diagnostics, weeks after the board upheld the validity of a second patent at issue in the same suit against Ariosa.
February 21, 2013
Laboratory Corporation of America Holdings partially ducked claims that it infringed Verinata Health Inc. and Stanford University's patents on prenatal tests, but it remains on the hook for claims that it indirectly infringed by taking blood for the tests, a California federal judge ruled Wednesday.
October 29, 2012
Stanford University's board of trustees and Verinata Health Inc. sued prenatal blood test maker Ariosa Diagnostics in California federal court Wednesday, alleging the company's Harmony prenatal test for Down syndrome and other fetal chromosomal disorders infringes a Stanford patent.